Preclinical

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Protein BIOMARKER Strategies

By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease state or a drug… Read More

#Archive

#Analysis #Biochemistry #Business #Chemistry #Clinical specialities #Drug development #Drug discovery #Lead discovery #Pharmacology #Preclinical #RNA

A business model for sustainable, strategic relationships

A business model for sustainable, strategic relationships By Dr Douglas J. Squires and Dr James E. McClurg Historically relationships between CROs and pharmaceutical and biotech companies, and the results of these relationships, have not met shared expectations for strategic value exchange. This article presents a business model for achieving a… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Biochemistry #Biomarkers #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High throughput screening #In Silico Biology #Lead discovery #Microbiology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Target validation #Toxicology

Balancing Quantity and Quality in Drug Discovery

Balancing Quantity and Quality in Drug Discovery By Eva-Lotta Allan There is a need to innovate in order to stay ahead, a need to maximise the value of the R&D engine by increasing the flow of novel drug candidates and yet, reduce the time to market. Does access to more… Read More

#Archive

#Animal models #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Immunology #Lead discovery #Oncology #Pharmokinetics #Preclinical #RNA #Sequencing #Stem cells #System biology #Systems biology

Second-Generation Protein Drugs

Second-Generation Protein Drugs By Dr Jeffrey C.Way The first biotech revolution was catalysed in the late 1970s with the development of recombinant DNA technology. This revolution generated numerous billion-dollar protein drugs such as erythropoietin and the interferons. Now that the patents on these drugs are expiring, will second generation proteins,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Immunology #Lead discovery #Molecular medicine #Organic chemistry #Pharmacology #Preclinical #Regulatory #Stem cells #System biology

New Visions in Ophthalmic Drug Development

New Visions in Ophthalmic Drug Development By Dr Benjamin R. Yerxa, Dr Ward M. Peterson and Robin S.Whitsell Over the last 10 years we have seen the introduction of several new 'ophthalmology only' pharmaceutical products emerge such as Trusopt (dorzolamide, Merck) and Xalatan (latanoprost, Pharmacia). Innovative products such as these… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #System biology #Systems biology #Target validation

The New Blockbuster Drugs – Healthcare packages for particular disease pathologies

The New Blockbuster Drugs - Healthcare packages for particular disease pathologies By Dr Nick Davies and Dr Steve Arlington With the cost of bringing a new drug to market now exceeding $800 million there is no doubt that the pharmaceutical industry has to fundamentally address the way in which it… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #Imaging #Lead discovery #Molecular medicine #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #System biology #Target validation #Therapeutics

CNS Drug Discovery – Realising the dream

CNS Drug Discovery - Realising the dream By Dr Julie C. Barnes and Dr Ann G. Hayes Over the years, the discovery of drugs for treating neurological and psychiatric diseases has proven to be one of the highest risk areas in the pharmaceutical industry. Despite the huge resources that have… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Preclinical #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Benchmarking chemistry functions within pharmaceutical drug discovery and preclinical development

By Dr Roger A. Edwards, Dr Kai Zhang and Louise Firth Different companies have employed various techniques and strategies for addressing productivity issues in the chemistry functions within pharmaceutical discovery and preclinical development. We benchmarked lead optimisation, clinical candidate selection, and chemistry support for preclinical development before IND filing in… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Biochemistry #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Pharmacology #Preclinical #Regulatory #RNA #Stem cells #Toxicology

Obesity – The 21st century disease

Obesity - The 21st century disease By Diane L. McBay and Dr Colin T. Dourish Obesity will be the leading cause of death and disability in the 21st century. This epidemic is largely attributable to increasingly sedentary lifestyles and the abundance of tasty, high-fat foods. Obesity increases the risk of… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Pharmacology #Preclinical #RNA #Screening #Stem cells #Target validation

Channelling Drug Discovery – Current trends in ion channel drug discovery research

Channelling Drug Discovery - Current trends in ion channel drug discovery research By Dr David Owen and Andrew Silverthorne Ion channels are proteins that span cell membranes thus forming conduits or 'channels' through which charged ions such as sodium and potassium can pass across a normally impermeant barrier such as… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Pharmacogenomics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Business strategy for implementation of biomarkers in drug development

Business strategy for implementation of biomarkers in drug development By Miles Flamenbaum With pharmacoproteomic biomarkers being the subject of focus among regulatory agencies as well as research institutions, many pharmaceutical companies are increasing their interest and investment in biomarker strategies. This article discusses the potential for new efficiencies and cost… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genomics #High throughput screening #Lead discovery #Lead optimisation #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Target validation #Toxicology

From raw data in the laboratory to information availability in the enterprise

From raw data in the laboratory to information availability in the enterprise By Dieter Kreusel If pharmaceutical or biotechnology companies could measure their success merely on the volume of raw data accumulated from screening assays and pre-clinical testing, they would be basking in the glow of unprecedented success. Companies are… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Pathology #Pharmacogenomics #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics #Toxicology

Toxicogenomics – Insights into the present and future

By Dr Patrick J. Vojta, Vincent P. Kazmer and Dr Larry D. Kier Adverse drug responses are an important post-marketing public health issue, occurring many times in subsets of treatment populations. Promising new approaches to predicting physiological responses to drugs are focused on genomic responses or toxicogenomics (1). This article… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Business #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Preclinical #Regulatory #RNA #Screening #Sequencing #System biology #Target validation #Therapeutics

A Revolution in R&D – The managerial challenges

The genomics revolution is poised to sweep aside the old economics of pharmaceutical R&D. The biotechnology and pharmaceutical industries; and perhaps healthcare delivery in general; are on the brink of transformation, and companies that embrace the revolution in the right way stand to reap enormous benefits. Developing a new drug… Read More

#Archive

#Analysis #Animal models #Automation / robotics #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Lead discovery #Molecular medicine #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #System biology #Target validation #Therapeutics #Toxicology

New Developments in Analgesia

New Developments in Analgesia By Dr Susan Boyce, Dr Zahid Ali and Dr Raymond G. Hill Novel therapies for pain and headache are major medical needs and constitute a continued opportunity. Novel treatments are likely to arise from a better understanding of both the pathophysiology of clinical pain conditions and… Read More

#Archive

#Analysis #Biomarkers #Business #Clinical specialities #Drug development #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Molecular medicine #Oncology #Pathology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology

Pharmacogenetics – A review of concepts and contents

By Professor Klaus Lindpaintner Pharmacogenetics represents a logical and consequent step in the history of medicine, but what are the immediate benefits and where do the hurdles lie in its implementation? It is common knowledge that today’s pharmacopea – in as much as it represents enormous progress if compared with… Read More

#Archive